Investments For A Better World!

Hardenbrook Group invests in the technology and life sciences sectors including medical technologies, pharmaceuticals, digital health, software, big data and AI.

We seek opportunities that provide a positive impact on improving health and wellbeing at scale.

We invest, commercialize, and bring our projects to life by listing them on stock exchanges in North America.

Our Investment Model & Deal Flow

Leveraging a merchant banking model, Hardenbrook Group works with world class research-intensive organizations (including large tier 1 Universities) to identify valuable intellectual property to invest, commercialize and take public on stock exchanges in North America.

Our Recent Deal

The founders of Hardenbrook Group negotiated and secured this very important project conducting clinical trials to improve mental health conditions.

MindBio is one of a few public listed biopharma companies with two fully funded Phase 2 clinical trials and the only one listed in North America that is specializing in a scalable microdosing treatment model.

After securing the project, the founders provided the funding, appointed a highly experienced management team and board and then listed the company on the Canadian Securities Exchange. The Company is progressing both its drug development program and capital market strategy as it heads towards a NASDAQ listing.

Investment Pathway

  • Deal Flow

    We source opportunities that can make a large positive impact. We like health and medical technologies, AI and companies with rich defendable IP. We invest in companies that can scale globally.

  • Investment

    We make investments for a better world! We invest our own capital and also invite accredited, wholesale, and institutional investors into our opportunities. Our focus is to fund R&D, product develop, commercialiszation and sales and expansion activities.

  • Spin-out and Listings

    We have extensive equity capital markets experience in Australia and North America. Our strategy is to complete multiple listings per year. We make sure our portfolio companies are well capitalized and then take them public.

Current Projects In Development

We are working on several large scale opportunities in medical sectors for Autism and Asthma, AI and big data, medical devices, agriculture biopharma, AI powered manufacturing, aged care, and more.

Q&A

  • The history of the New York Stock Exchange begins with the signing of the Buttonwood Agreement by twenty-four New York City stockbrokers and merchants on May 17, 1792, outside of 68 Wall Street under a Buttonwood tree. The 24 brokers who signed the agreement, thus becoming the first NYSE members, included John A Hardenbrook.

  • Unfortunately no. Hardenbrook only funds its own deals under a merchant banking model. We source our own deal flow, actively manage them and then take them public by listing on North American stock exchanges.

  • If you are an accredited/wholesale investor you can co-invest in our deals, by invitation only. Please register with your interest by contacting us.

    You can also get exposure to our portfolio and activities when Hardenbrook goes public (annoucement soon).

  • We have relationships and agreements with research organizations. This gives us access to a large pool of opportunities.

  • We look for good quality management, experienced board, defendable & innovative intellectual property, highly scalable products that can be sold globally, a clear business model and identifiable distribution pathway.

    We back companies that can change the world, solve problems for large groups of people and make the world a better place.

Contact Us

Please use this form to contact us